Flourishglobal Peptide Biotech (revision 20)
Old revision·09:15, 5 Jun 2025·CounterfeitCato
| Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. |
| Trading name | FGP |
| Other designations | FGP Biotech, Flourishglobal Peptide Biotech (Chengdu) |
| Identity | |
| Founded | 2019 |
| Headquarters | Chengdu, China |
| Industry | Research-compound supply |
| Shop domain | Visit FGP |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| Organisation infobox · conventions | |
Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. (trading as FGP; flourishglobalpeptide.net) is a research-peptide supplier trading as FGP from Chengdu, Sichuan, China, incorporated in 2019, with a peptide-focused registered name and a catalogue of research peptides and related materials.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Incorporated in 2019 in Chengdu, the organisation is one of two covered here that are based outside the eastern coastal cluster, the other being in Hunan.[1] Its registered name includes "Peptide Biotech", making it one of the few whose registration matches its trading activity closely.
Chengdu's position inland has a practical consequence that appears in purchaser reports: outbound shipments route through coastal or regional hubs, adding a domestic leg before the international one. Reported transit times have been slightly longer than for coastal comparators, and reported temperature exposure correspondingly greater on the temperature-sensitive lines.[5]
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Reports describe lyophilised material with a batch certificate and, for the incretin range, insulated packaging with a phase-change pack rather than a simple gel pack.[5] That is a more considered cold-chain arrangement than most reports describe, and it is consistent with an origin that requires a longer domestic leg.
Certificates in submitted material have reported purity and appearance; water figures have appeared on some and not others, which suggests the practice is not standardised.[5][6]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide, retatrutide | Certificate, purity; water sometimes |
| Research peptides | Repair, secretagogue, cosmetic peptides | Certificate, purity |
| SARMs | Bulk | Certificate, purity |
| Raw materials and oils | Bulk | Certificate, limited detail |
References
- ^ a b National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.